Citations

Clear

2960 citation(s) found for "Kim, P".

Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Mahoney, Michelle R., Allmer, Cristine, Pitot, Henry C., Kim, George , Donehower, Ross C. , Fitch, Tom R., Erlichman, Charles , Philip, Philip A. , Thomas, James P. , Picus, Joel

Mayo Clinic

Journal of Clinical Oncology | September 16, 2005 | Volume: 23 | Issue: 27 | Pages: 6657-6663

10.1200/jco.2005.14.696 | PMID 16170173 Get It

Purpose Epidermal growth factor receptor/human epidermal growth factor receptor 1 (EGFR/HER1) and ligand expression is frequently seen in hepatocellular cancers (HCCs). Erlotinib (Tarceva, OSI-774; OSI Pharmaceuticals, Melville, NY) is a receptor tyrosine kinase inhibitor with specificity for the EGFR/HER1. Methods The primary objective of this study was to determine the proportion of patients with advanced HCC who were progression-free at 6 months. Patients with either unresectable or metastatic disease were studied. Only one prior systemic or locoregional therapy was allowed. Erlotinib was given continuously at a dose of 150 mg per day orally. Results Thirty-eight patients with HCC were enrolled. Median age of the patients was 69 years (range, 27 to 83 years). A majority of patients (63%) had an Eastern Cooperative Oncology Group performance status of 1. Forty-seven percent of patients had received prior chemotherapy for advanced HCC. EGFR/HER1 expression was detected in 88% of the patients. Median number of cycles per patient was two (range, 1 to 26). Twelve (32%; CI 95%, 18 to 49) of the 38 patients with HCC were progression-free at 6 months. Three patients had partial radiologic responses of duration of 2, 10, and 11 months, respectively. Disease control was seen in 59% of the patients. Median overall survival time was 13 months. Ten patients (26%) had toxicity-related dose reductions of erlotinib. Grade 3/4 skin toxicity or diarrhea was encountered in five and three patients, respectively. Conclusion Results of this trial suggest a benefit for EGFR/HER1 blockade with erlotinib in patients with HCC manifested by disease control. Additional studies with erlotinib as a single agent or in combination with other agents are warranted.
Preserving Olfactory Function in Anterior Craniofacial Surgery through Cribriform Plate Osteotomy Applied in Selected Patients
Feiz‐Erfan, Iman , Han, Patrick P., Spetzler, Robert F., Horn, Eric M., Klopfenstein, Jeffrey D., Kim, Louis J. , Porter, Randall W., Beals, Stephen P., Lettieri, Salvatore C. , Joganic, Edward F., Kim, Louis J.

Mayo Clinic

Operative Neurosurgery | July 13, 2005 | Volume: 57 | Issue: suppl_1 | Pages: 86-93

10.1227/01.neu.0000163487.94463.4a | PMID 15987573 Get It

AbstractOBJECTIVE:Olfaction is often sacrificed to gain access to the cranial base in anterior craniofacial surgery. We describe the long-term results of olfactory function in patients who underwent anterior craniofacial surgery and a cribriform plate osteotomy to preserve olfaction.METHODS:Between 1992 and 2004, 28 patients underwent 29 cribriform plate osteotomies in an attempt to preserve olfaction during anterior craniofacial surgery performed through modified extended transbasal approaches. Patients' charts and office notes were reviewed retrospectively. Formal olfactory testing was available in 5 patients, but most data were based on patients' subjective reports of olfaction. Olfactory preservation was defined by the subjective ability to detect fumes such as coffee, chocolate, roses, and orange juice regardless of the intensity of the sensation. Follow-up was based on phone calls to patients.RESULTS:Four patients were lost to follow-up and excluded. Therefore, follow-up was available in 24 patients after 25 procedures. On the basis of patients' subjective reports, olfaction was spared in 22 patients after 23 procedures (92%) and was confirmed objectively in the five patients formally tested. After surgery, only two patients were anosmic.CONCLUSION:Olfaction can be preserved in selected patients undergoing anterior craniofacial surgery. At least 1 cm of nasal mucosa should remain attached to the cribriform plate, which can be achieved by including the nasal bone in the osteotomy of the orbital bar. A medial orbital canthopexy is therefore necessary after these procedures.
Physiology Is a Stronger Predictor of Survival than Pathology in Fibrotic Interstitial Pneumonia
Jegal, Yangjin , Kim, Dong Soon, Shim, Tae Sun , Lim, Chae‐Man , Lee, Sang‐Do , Kim, Woo Sung , Lee, Jin Seong , Kitaichi, Masanori, Colby, Thomas V. , Koh, Younsuck , Kim, Won Dong , Travis, William D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | January 7, 2005 | Volume: 171 | Issue: 6 | Pages: 639-644

10.1164/rccm.200403-331oc | PMID 15640368 Get It

Abstract The histopathologic pattern provides the most important prognostic marker for idiopathic interstitial pneumonia; however, studies have suggested that short-term changes in lung function may be more important. We investigated the prognostic factors for fibrotic interstitial pneumonia. The clinical features and follow-up course of 179 patients (131 with idiopathic pulmonary fibrosis and 48 with nonspecific interstitial pneumonia; 41 fibrotic types and 7 cellular) were analyzed retrospectively. The lung function indices improved or stabilized in most patients with fibrotic nonspecific interstitial pneumonia in contrast to the deterioration or stable condition of most patients with idiopathic pulmonary fibrosis. The 5-year survival of patients with fibrotic nonspecific interstitial pneumonia (76.2%) was better than for those with idiopathic pulmonary fibrosis (43.8%) (p = 0.007). Multivariate analysis at the time of presentation revealed that pathologic pattern, age, and diffusion capacity had important prognostic implications. However, after 6 months of follow-up, changes in FVC, initial diffusion capacity, and sex were the only independent prognostic factors, with no additional prognostic information conferred by the histologic diagnosis. Our data confirmed the importance of physiological parameters including short-term change in FVC. However, at the time of diagnosis, histopathology was important for the prediction of prognosis and future change in lung function.
Rapid Assembly of Amyloid-β Peptide at a Liquid/Liquid Interface Produces Unstable β-Sheet Fibers
Nichols, Michael R. , Moss, Melissa A. , Reed, Dana Kim , Hoh, Jan H. , Rosenberry, Terrone L.

Mayo Clinic

Biochemistry | January 4, 2005 | Volume: 44 | Issue: 1 | Pages: 165-173

10.1021/bi048846t | PMID 15628857 Get It

Chemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484
Horning, Sandra J., Weller, Edie, Kim, KyungMann, Earle, John D., Glick, John H., O’Connell, Michael J. , Habermann, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | June 22, 2004 | Volume: 22 | Issue: 15 | Pages: 3032-3038

10.1200/jco.2004.06.088 | PMID 15210738 Get It

Purpose To compare low-dose (30 Gy) radiotherapy (RT) with observation (OBS) in limited-stage aggressive lymphoma patients achieving complete remission (CR) after chemotherapy, and to measure conversion from partial response (PR) to CR with high-dose (40 Gy) RT. Patients and Methods From 1984 to 1992, stage I (with risk factors) and II adults with diffuse aggressive lymphoma in CR after eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) were randomly assigned to 30 Gy involved-field RT or OBS. PR patients received 40 Gy RT. Results Among 172 CR patients, the 6-year disease-free survival (DFS) was 73% for low-dose RT versus 56% for OBS (two-sided P = .05). Failure-free survival (two-sided P = .06), and time to progression (two-sided P = .06) also favored RT. Intent-to-treat analyses yielded similar results. No survival differences were observed. Three RT versus 15 OBS patients relapsed in initial disease sites. At 6 years, failure-free survival was 63% in PR patients; conversion to CR did not significantly influence clinical outcome. Conclusion For patients in CR after CHOP, low-dose RT prolonged DFS and provided local control, but no survival benefit was observed. The majority of PR patients were event-free at 6 years despite residual radiographic abnormalities. Future efforts should be directed toward improved imaging and more effective systemic therapies.
Difficulties with the “N + 7 Rule” in endoscopic anterior cruciate ligament reconstruction
Pagnano, Mark W., Kim, Chang-Woo , Huie, Gordon, Pagnano, Mark W. , Scott, W. Norman

Mayo Clinic

Arthroscopy | June 2, 2004 | Volume: 13 | Issue: 5 | Pages: 597-599

10.1016/s0749-8063(97)90186-9 | PMID 9343648 Get It

Abstract In an effort to facilitate the use of interference screw fixation in the tibia, a method to orient the tibial tunnel termed the “N + 7 Rule” was prospectively applied to 60 consecutive endoscopic anterior cruciate ligament reconstructions performed by a single surgeon. Four cases were excluded because a breach in the described protocol for application of the N + 7 rule was identified at the time of the operation. Of the remaining 56 cases, 28 (50%) were fixed with an interference screw on the tibia, whereas 28 (50%) required fixation with sutures tied over a post. The 28 cases not amenable to interference screw fixation included 17 cases in which the tibial tunel was too long and 11 cases in which the tunnnel was too short. It appears that the applicability of the N + 7 rule to an individual surgeon's practice may be altered by small variations in operative technique.
Differential Effects of Interleukin-7 and Interleukin-15 on NK Cell Anti-Human Immunodeficiency Virus Activity
Schnepple, David, Nie, Zilin , Sanchez-Dardon, Jaime, Mbisa, Georgina, Mihowich, Jennifer, Hawley, Nanci, Narayan, Shanil, Kim, John E., Badley, Andrew D. , Lum, Julian J. , Lynch, David H. , Badley, Andrew D

Mayo Clinic

Journal of Virology | May 12, 2004 | Volume: 78 | Issue: 11 | Pages: 6033-6042

10.1128/jvi.78.11.6033-6042.2004 | PMID 15141001 Get It

ABSTRACTThe ability of interleukin-7 (IL-7) and IL-15 to expand and/or augment effector cell functions may be of therapeutic benefit to human immunodeficiency virus (HIV)-infected patients. The functional effects of these cytokines on innate HIV-specific immunity and their impact on cells harboring HIV are unknown. We demonstrate that both IL-7 and IL-15 augment natural killer (NK) function by using cells (CD3−CD16+CD56+) from both HIV-positive and -negative donors. Whereas IL-7 enhances NK function through upregulation of Fas ligand, the effect of IL-15 is mediated through upregulation of tumor necrosis factor-related apoptosis-inducing ligand. The difference in these effector mechanisms is reflected by the ability of IL-15-treated but not IL-7-treated NK cells to reduce the burden of replication-competent HIV in autologous peripheral blood mononuclear cells (PBMC) (infectious units per million for control NK cells, 6.79; for IL-7-treated NK cells, 236.17; for IL-15-treated cells, 1.01;P= 0.01 versus control). In addition, the treatment of PBMC with IL-15-treated but not IL-7-treated NK cells causes undetectable HIV p24 (five of five cases), HIV RNA (five of five cases), or HIV DNA (three of five cases). These results support the concept of adjuvant immunotherapy of HIV infection with either IL-7 or IL-15 but suggest that the NK-mediated antiviral effect of IL-15 may be superior.
Acute Monocytic Leukemia (French-American-British classification M5) Does Not Have a Worse Prognosis Than Other Subtypes of Acute Myeloid Leukemia: A Report From the Eastern Cooperative Oncology Group
Tallman, Martin S. , Paietta, Elisabeth , Bennett, John M. , Dewald, Gordon W., Cassileth, Peter A., Wiernik, Peter H. , Rowe, Jacob M. , Kim, Haesook T.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2004 | Volume: 22 | Issue: 7 | Pages: 1276-1286

10.1200/jco.2004.08.060 | PMID 14970186 Get It

Purpose Acute monocytic leukemia is a distinct subtype of acute myeloid leukemia (AML) with characteristic biologic and clinical features. This study was designed to compare the outcome of patients with M5 to that of other subtypes of AML, and to identify differences in M5a and M5b. Patients and Methods We reviewed all patients with AML M5 entered in three clinical trials for newly diagnosed AML conducted by the Eastern Cooperative Oncology Group between 1989 and 1998. Eighty-one patients, 21 with M5a and 60 with M5b, were identified. Results The complete remission rate was 62% for all patients with M5; 52% for patients with M5a and 65% for patients with M5b (P = .3), and 60% for the 1,122 patients with non-M5 AML entered on the same clinical trials (P = .8 for M5 v non-M5). The 3-year disease-free survival was 26% for all M5 patients; 18% for M5a and 28% for M5b (P = .31), and 33% for non-M5 patients (P = .13 for M5 v non-M5). The 3-year overall survival was 31% for all M5 patients; 33% for M5a and 30% for M5b (P = .65), and 30% for non-M5 (P = .74 for M5 v non-M5). The karyotypes of patients with AML M5 were heterogeneous. CD11b was the only leukemic cell antigen expressed differently in M5a (53%) compared to M5b (77%) to a significant degree (P = .02). Conclusion AML M5 represents an immunologically heterogeneous population similar to non-M5 AML with a prognosis that is not dependent on morphology. The disease-free survival and overall survival of patients with M5a, M5b, and non-M5 appear not to differ with currently available therapy.
Estimation of Left Ventricular Function in Right Ventricular Volume and Pressure Overload. Detection of Early Left Ventricular Dysfunction by Tei Index.
Otsuji, Yutaka , Seward, James B., Tei, Chuwa , Kim, Won Ho

Mayo Clinic

Japanese Heart Journal | January 14, 2004 | Volume: 40 | Issue: 2 | Pages: 145-154

10.1536/jhj.40.145 | PMID 10420876 Get It

Spontaneous fusion of cells between species yields transdifferentiation and retroviral transfer in vivo
Ogle, Brenda M. , Butters, Kim A., Plummer, Timothy B., Ring, Kevin R., Litzow, Mark R. , Platt, Jeffrey L. , Knudsen, Bruce E. , Cascalho, Marília

Mayo Clinic

The FASEB Journal | January 12, 2004 | Volume: 18 | Issue: 3 | Pages: 548-550

10.1096/fj.03-0962fje | PMID 14715691 Get It

Human cells can fuse with damaged or diseased somatic cells in vivo. Whether human cells fuse in vivo in the absence of disease and with cells of disparate species is unknown. Such a question is of current interest because blood exchanges between species through direct physical contact, via insect vectors or parasitism, are thought to underlie the transmission of zoonotic agents. In a model of human‐pig chimerism, we show that some human hematopoietic stem cells engrafted in pigs contain both human and porcine chromosomal DNA. These hybrid cells divide, express human and porcine proteins, and contribute to porcine nonhematopoietic tissues. In addition, the hybrid cells contain porcine endogenous retroviral DNA sequences and are able to transmit this virus to uninfected human cells in vitro. Thus, spontaneous fusion can occur in vivo between the cells of disparate species and in the absence of disease. The ability of these cell hybrids to acquire and transmit retroviral elements together with their ability to integrate into tissues could explain genetic recombination and generation of novel pathogens.